創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
19/07/08 GEM087 Corticosteroid receptor agonist Refer to Note Refer to Note Small molecule
Preclinical Indication: Ocular inflammation and Meibomian gland dysfunction (MGD)
Route: Topical (eye drop)

New ophthalmic suspension of loteprednol etabonate (LE) with improved ocular bioavailability.
- Drug exposure in aqueous humor and iris ciliary body are about 6 fold higher than Lotemax® in rabbits.
- The new formulation of LE administered twice a day for the treatment of adjuvant induced chronic uveitis model in rabbits showed a similar efficacy with lotemax administered four times a day
問合せ
19/07/08 GEM086 VEGF inhibitor Refer to Note Refer to Note Small molecule
Preclinical Indication: Wet AMD (age-related macular degeneration)
Route: Topical (eye drop)

New formulation of axitinib designed to deliver the drug across ocular tissues to choroid and retina.
-Greatly enhancing aqueous solubility (4000-fold solubility enhancement)
- High drug exposure in retina (300-fold of IC50)
- Potential for substitution of anti-VEGF Ab treatment via intravitreal injection
問合せ
19/07/08 GEM085 Anti-Her2 antibody drug conjugates (ADCs) Cancers with moderate to high Her2 expression IV Protein
Preclinical The anti-Her2 ADCs consiting of trastuzumab and novel linker-drugs.
- 10-100 fold higher potency comparting to Kadcyla®
- High theraperutic window (MED ~1-2 mg/kg, MTD ~100 mg/kg in mice)
- High tumor growth inhibition rate (90-100%) with high stability in vivo
問合せ
19/07/04 GEM084 MRI contrast agent formulation Diagnosis of bladder cancer see Note Other
Phase 2 ready Route: Topical (Intravesical)

New formulation consisting of iron and gadolinium for intravesical instillation. A pilot trial in humans provided evidence that the MRI contrast agent can be detected in the bladder wall. No treatment-related AEs were observed.
問合せ
19/07/04 GEM083 Vasoconstriction and anti-inflammatory action Hemorrhagic Cystitis see Note Small molecule
Phase 2 Route: Topical (Intravesical) 

Pre-liposomal lyophilate containing tacrolimus.
POC achieved in animal models of both chemo-cystitis and radiation cystitis.
POC achieved in first-in-man experience treating severe recurrent hemorrhagic cystitis. Orphan drug designation granted.
問合せ
19/06/27 GEM082 Modified IL-1 receptor antagonist (IL-1RA) Refer to Note Intra-articular Protein
Preclinical Indication: Osteoarthritis, gout, anterior cruciate ligament (ACL) injury

Single intra-articular injection of Anakinra (rhIL-1RA) improved OA symptoms vs placebo in clinical Phase-2 but the effect was short-lasting.
GEM082 showed prolonged retention in the joint and sustained efficacy. GEM082 targets directly the biology of the inflammasome, involved in acute OA pain flares, without the adverse effects of steroids.
Avaliable for licensing to Japan, China and Taiwan.
問合せ
19/06/12 GEM081 Oncolytic virus Refer to Note IM Virus
Phase 2 ready Indication:
Solid tumor (Melanoma, GI cancer etc.)

Genetically non-modified and non-pathogenic virus with
- oncolytic, oncotropic and immunomodulating properties
- excellent safety profile
- various development options
Medicine containing this virus is already approved for treatment for many years in certain countries.
This virus has established fully GMP certified API production
問合せ
19/06/06 GEM080 Novel cell surface receptor for insoluble protein involved in Parkinson's/Lewy body diseases Parkinson's diseases, Lewy body disease NA NA
Preclinical Cell surface receptors for insoluble protein involved in Parkinson's disease/Lewy body disease which were newly identified by utilizing artificial liposomes embedded with endogenous membrane proteins (see TGEM025 in Technology). Antagonists of the receptors are expected to be effective on Parkinson's/Lewy body diseases. 問合せ
19/06/06 GEM079 Novel cell surface receptor for angiogenesis regulation Cancers, chronic inflammation, diabetic retinopathy , myocardial infarction, etc NA NA
Preclinical Cell surface receptor involved in angiogenesis which was newly identified by utilizing artificial liposomes embedded with endogenous membrane proteins (see TGEM025 in Technology). Agonists of the receptor are expected to be effective on diseases where angiogenesis is involved as an aggravating factor. 問合せ
19/05/30 GEM078 Hyaluronic acid-based nanocarriers of cisplatin Head and neck cancer, pancreatic cancer, melanoma with metastasis IV Small molecule
Preclinical CD44 targeting and higher stability lead to enhance lymphatic delivery and inhibit cancer with lymphatic metastasis.
Chemodrug encapsulated by nanocarriers minimize systemic toxicities.
Convenient dosing by intravenous injection.
問合せ